BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (NASDAQ:BBLG, BBLGW)) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets,
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets,
BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets,
BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (NASDAQ:BBLG, BBLGW)) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets,
BURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (NASDAQ:BBLG, BBLGW)) ("Bone Biologics," or the "Company"), a developer of orthobiologic products for spine fusion
BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets,
BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets,
BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets,
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of
Bone Biologics Corporation ("Bone Biologics" or the "Company) (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common
